Terns Pharmaceuticals Inc
TERN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.77B
Close$
$5.62
89.4% downside
Current Fair Value
89.4% downsideOvervalued by 89.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.77 Billion |
|---|---|
| Enterprise Value | $4.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.03 |
| Beta | -0.38 |
| Outstanding Shares | 93,166,571 |
Return
| Return on Equity | -9.56% |
|---|---|
| Return on Assets | -9.39% |
| Return on Invested Capital | -10.92% |
Valuation & Multiples
| P/E Ratio | -51.28 |
|---|---|
| PEG | -630.8 |
| Price to Sales | - |
| Price to Book Ratio | 5.3 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -38.57 |
| Enterprise Value to Net Income | -45 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6409▲ 44.93% |
|---|---|
| Total Calls | 7,168,620▲ 465.66% |
| Total Puts | 4,594,600▲ 1791.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 133.86%▲ 0.18% |
|---|---|
| Total Invested | $6.56B▲ 32.47% |
| Investors Holding | 354▲ 99.00% |
ESG Score
No data
About Terns Pharmaceuticals Inc
30 employeesTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chr...